PDF
ePub
Citation
Print
Abstract
Pelvic inflammatory disease (PID), the infection and inflammation of a woman's upper genital tract, is a frequent cause of infertility, ectopic pregnancy, and chronic pelvic pain among women of childbearing age. The management of PID has been largely based on the protocols issued by national or international institution. These guidelines recommended a broad-spectrum antibiotherapy in which quinolones continue to hold a key place. Yet, several significant facts such as the increase of quinolone-resistant gonococci and the emergence of 'new' pathogens have recently led us to reconsider the paradigms of the management of PID. This article reviewed lately published literatures on new bacteriological finding and recent antibiotics trials to delinate optimal regimen in managing PID.
Figures and Tables
Table 1
2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines; pelvic inflammatory disease
*Quinolones should not be used to treat those with a history of recent foreign travel or partner travel or those with infections acquired in California or Hawaii or in other areas with increased prevalence of quinolone-resistant Neisseria gonorrhoeae infection.
†Quinolones should not be used to treat those with a history of recent foreign travel or partner travel or those with infections acquired in California or Hawaii or in other areas with increased prevalence of quinolone-resistant Neisseria gonorrhoeae infection.
References
1. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006. 55:1–94.
2. Ross J, Judlin P, Nilas L. European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2007. 18:662–666.
3. Royal College of Obstetricians and Gynaecologists. Management of acute pelvic inflammatory disease. Green-top Guideline No. 32, Nov 2008. [Internet]. c2010. [cited 2008 Nov]. London (UK): Royal College of Obstetricians and Gynaecologists;Available from: URL:
http://www.rcog.org.uk/search/node/green-top+guideline.
4. Boukes FS, Dekker JH, Wiersma TJ, Goudswaard AN. Summary of the practice guideline 'Pelvic inflammatory disease' (first revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd. 2007. 151:753–756.
5. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. [Internet]. 2010. [cited 2010 Jan]. Ottawa (Canada): Public Health Agency of Canada;Available from: URL:
http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php.
6. Sorbye IK, Jerve F, Staff AC. Reduction in hospitalized women with pelvic inflammatory disease in Oslo over the past decade. Acta Obstet Gynecol Scand. 2005. 84:290–296.
7. Simms I, Eastick K, Mallinson H, Thomas K, Gokhale R, Hay P, et al. Associations between Mycoplasma genitalium, Chlamydia trachomatis and pelvic inflammatory disease. J Clin Pathol. 2003. 56:616–618.
8. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002. 186:929–937.
9. Tapsall JW, Shultz TR, Lovett R, Munro R. Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Med J Aust. 1992. 156:143.
10. Gallay A, Bouyssou-Michel A, Lassau F, Basselier B, Sednaoui P. Neisseria gonorrhoeae infections in France in 2006: significant progression in women and persistent increase of ciprofloxacin resistance. Bull Epidémiol Hebdomadaire. 2008. 5-6:33–36.
11. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep. 2007. 56:332–336.
12. Lee K, Chong Y, Erdenechemeg L, Soon Song K, Hun Shin K. Incidence, epidemiology and evolution of reduced susceptibility to ciprofloxacin in Neisseria gonorrhoeae in Korea. Clin Microbiol Infect. 1998. 4:627–633.
13. Yoo J, Yoo C, Cho Y, Park H, Oh HB, Seong WK. Antimicrobial resistance patterns (1999-2002) and characterization of ciprofloxacin-resistant Neisseria gonorrhoeae in Korea. Sex Transm Dis. 2004. 31:305–310.
14. Ness RB, Kip KE, Hillier SL, Soper DE, Stamm CA, Sweet RL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005. 162:585–590.
15. Livengood CH. Bacterial vaginosis: an overview for 2009. Rev Obstet Gynecol. 2009. 2:28.
16. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005. 353:1899–1911.
17. Haggerty CL, Totten PA, Ferris M, Martin DH, Hoferka S, Astete SG, et al. Clinical characteristics of bacterial vaginosis among women testing positive for fastidious bacteria. Sex Transm Infect. 2009. 85:242–248.
18. Hebb JK, Cohen CR, Astete SG, Bukusi EA, Totten PA. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis. 2004. 190:2109–2120.
19. Haggerty CL, Totten PA, Astete SG, Ness RB. Mycoplasma genitalium among women with nongonococcal, nonchlamydial pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2006. 2006:30184.
20. Short VL, Totten PA, Ness RB, Astete SG, Kelsey SF, Haggerty CL. Clinical presentation of Mycoplasma genitalium Infection versus Neisseria gonorrhoeae infection among women with pelvic inflammatory disease. Clin Infect Dis. 2009. 48:41–47.
21. Haggerty CL, Totten PA, Astete SG, Lee S, Hoferka SL, Kelsey SF, et al. Failure of cefoxitin and doxycycline to eradicate endometrial Mycoplasma genitalium and the consequence for clinical cure of pelvic inflammatory disease. Sex Transm Infect. 2008. 84:338–342.
22. Ross JD, Cronje HS, Paszkowski T, Rakoczi I, Vildaite D, Kureishi A, et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sex Transm Infect. 2006. 82:446–451.
23. Rustomjee R, Kharsany AB, Connolly CA, Karim SS. A randomized controlled trial of azithromycin versus doxycycline/ciprofloxacin for the syndromic management of sexually transmitted infections in a resourcepoor setting. J Antimicrob Chemother. 2002. 49:875–878.
24. Malhotra M, Sharma JB, Batra S, Arora R, Sharma S. Ciprofloxacin-tinidazole combination, fluconazole-azithromicin-secnidazole-kit and doxycycline- metronidazole combination therapy in syndromic management of pelvic inflammatory disease: a prospective randomized controlled trial. Indian J Med Sci. 2003. 57:549–555.
25. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res. 2003. 31:45–54.
26. Savaris RF, Teixeira LM, Torres TG, Edelweiss MI, Moncada J, Schachter J. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007. 110:53–60.
27. Judlin P. Current concepts in managing pelvic inflammatory disease. Curr Opin Infect Dis. 2010. 23:83–87.
XML Download